Angiopoietin 1 counteracts vascular endothelial growth factor-induced blood-brain barrier permeability and alleviates ischemic injury in the early stages of transient focal cerebral ischemia in rats.
OBJECTIVE
To examine the effects of intraventricular pre-treatment with a combination of recombinant adeno-associated virus vectors encoding VEGF (rAAV-VEGF) and Ang1 (rAAV-Ang1) on early stroke in a rat model of transient middle cerebral artery occlusion (tMCAO).


METHODS
rAAV-VEGF/rAAV-Ang1 or rAAV-VEGF/rAAV-null vector was delivered into the lateral ventricles of 48 rats. Eight weeks later, the rats were subjected to tMCAO for 2 hours. During the early stages of ischemic reperfusion, VEGF and Ang1 expression levels, blood-brain barrier (BBB) permeability and cerebral microvessel density were determined and compared statistically between groups. Cerebral infarct volume and modified neurological severity scores (NSS) were also determined to evaluate the therapeutic efficacy of rAAV-VEGF/rAAV-Ang1.


RESULTS
Intraventricular application of rAAV-VEGF/rAAV-Ang1, 8 weeks before tMCAO, resulted in VEGF and Ang1 overexpression, and significantly decreased Evans blue permeability following ischemia (p<0.05). The microvessel density in the peri-infarct zone was significantly increased in the rAAV-VEGF/rAAV-Ang1 group compared with the rAAV-VEGF/rAAV-null group (p<0.05). Cerebral infarct volume and NSS in the rAAV-VEGF/rAAV-Ang1 group were significantly decreased compared with the rAAV-VEGF/rAAV-null group (p<0.05).


CONCLUSIONS
In cerebral ischemia, the combination of Ang1 and VEGF could be used early to promote the formation of mature neovessels and protect the injured cells, without inducing the side effects on BBB permeability. Early intraventricular injection of mixed rAAV-VEGF and rAAV-Ang1 may be a favorable therapeutic strategy in gene therapy for experimental stroke.
Zhao
Yingjie
Y
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical, Sciences and Peking Union Medical College, Beijing, China. yingjiezhao2008@sohu.com
Li
Zhaojian
Z
Wang
Renzhi
R
Wei
Junji
J
Li
Guilin
G
Zhao
Hao
H
D000704:Analysis of Variance; D042683:Angiopoietin-1 / Q000494:pharmacology*; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002199:Capillary Permeability / Q000187:drug effects*; D000229:Dependovirus / Q000378:metabolism; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D051381:Rats; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D042683:Angiopoietin-1; D042461:Vascular Endothelial Growth Factor A